AAIC 2025 Abstract
Update on the Development of SUVN‐I6107: A True Positive Allosteric Modulator of the Muscarinic M1 Acetylcholine Receptor for the Treatment of Dementia
By Vijay S. Benade, Anil Karbhari Shinde, Rajesh Kumar Badange, Show 10 more authorsRamakrishna V. S. Nirogi
Experiments in animalsInterventions
Abstract
Background: SUVN‐I6107 is a novel and selective muscarinic M1 Positive Allosteric Modulator (PAM) being developed for the treatment of dementia due to neurodegenerative disorders. In the current research, the pharmacological properties of SUVN‐I6107 in various animal models of cognitive deficits were investigated.
